Choline fenofibrate

Drug Profile

Choline fenofibrate

Alternative Names: ABT-335; Fenofibric acid; HEXA/ABT335; SLV 348; SLV348/ABT335; TriLipix

Latest Information Update: 12 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Developer AbbVie
  • Class Antihyperlipidaemics; Fibric acid derivatives; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia
  • No development reported Diabetic macular oedema

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 12 Oct 2015 No recent reports on development identified - Phase-III for Hyperlipidaemia (Combination therapy) in Puerto Rico (PO)
  • 15 Jul 2013 Generic equivalent launched in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top